DNA methylation associates with survival in non-metastatic clear cell renal cell carcinoma

Evelönn, Emma Andersson; Landfors, Mattias; Haider, Zahra; Köhn, Linda; Ljungberg, Börje; Roos, Göran; Degerman, Sofie

doi:10.1186/s12885-019-5291-3

BMC Cancer

Table 2 Clinicopathological parameters, methylation and genetic alternations and its relation to ccRCC progression

From: DNA methylation associates with survival in non-metastatic clear cell renal cell carcinoma

		M0-PF (n = 64)	M0-P (n = 23)	M1 (n = 28)	p-value all groups of patients	p-value M0-PF vs. M0-P	p-value M0-PF vs. M1	p-value M0-P vs. M1
Age	(median ± SD)	68.5 ± 11.2	64.0 ± 12.7	63.5 ± 11.0	0.103¹	0.165	0.093³	0.857³
Gender	Male	34	11	21	0.087²	0.663²	0.049²	0.046²
Gender	Famale	30	12	7	0.087²	0.663²	0.049²	0.046²
Tumor diameter (mm)	(median ± SD)	50.0 ± 30.7	90.0 ± 45.7	100.0 ± 35.7	< 0.001¹	0.001³	< 0.001³	0.107³
Morphological grade	G1	14	2	0	< 0.001²	0.006²	< 0.001²	0.199²
	G2	31	8	7
	G3	18	8	8
	G4	1	5	12
T Stage	T1	42	7	1	< 0.001²	0.010²	< 0.001²	0.054²
	T2	11	6	8
	T3	11	10	18
	T4	0	0	1
TNM	I	42	7	0	< 0.001²	0.001²	< 0.001²	< 0.001²
	II	11	3	0
	III	11	13	0
	IV	0	0	28
Follow Up Status	Alive	38	1	0	< 0.001²	< 0.001²	< 0.001²	0.126²
	Alive, disease	0	4	1
	Dead, ccRCC	0	18	27
	Dead	26	0	0
Cluster	A	57	13	11	< 0.001²	0.001²	< 0.001²	0.220²
Cluster	B	7	10	17	< 0.001²	0.001²	< 0.001²	0.220²
PMC status	Low	36	4	–	–	0.001	–	–
PMC status	High	28	19	–	–	0.001	–	–
DM-CpGs, tot. Number	(median ± SD)	9191 ± 4779	10,460 ± 3698	12,996 ± 4448	0.001¹	0.227³	0.005³	0.130³
Hypermethylated CpGs	(median ± SD)	5826 ± 2820	7617 ± 2990	8233 ± 448	0.015¹	0.025³	0.001³	0.150³
Hypomethylated CpGs	(median ± SD)	2810 ± 3173	2843 ± 2990	2688 ± 4249	0.970¹	0.810³	0.905³	0.910³
Mitotic Age	(median ± SD)	0.16 ± 0.05	0.18 ± 0.05	0.18 ± 0.06	0.047¹	0.132³	0.021³	0.538³
Loss 1p	WT	42	19	18	0.272²	0.127²	0.901²	0.145²
Loss 1p	Loss	22	4	10	0.272²	0.127²	0.901²	0.145²
Loss 3p	WT	11	3	4	0.288²	0.643²	0.729²	0.898²
Loss 3p	Loss	53	20	24	0.288²	0.643²	0.729²	0.898²
Loss 3q	WT	45	20	21	0.995²	0.115²	0.646²	0.285²
Loss 3q	Loss	19	3	7	0.995²	0.115²	0.646²	0.285²
Gain 5q	WT	30	11	13	0.054²	0.938²	0.969²	0.921²
Gain 5q	Gain	34	12	15	0.054²	0.938²	0.969²	0.921²
Loss 6q	WT	50	22	26	0.027²	0.056²	0.086²	0.673²
Loss 6q	Loss	14	1	2	0.027²	0.056²	0.086²	0.673²
Gain 7p	WT	51	21	17	0.061²	0.206²	0.057²	0.013²
Gain 7p	Gain	13	2	11	0.061²	0.206²	0.057²	0.013²
Gain 7q	WT	51	21	18	0.598²	0.206²	0.116²	0.024²
Gain 7q	Gain	13	2	10	0.598²	0.206²	0.116²	0.024²
Loss 8p	WT	47	15	18	0.002²	0.455²	0.375²	0.945²
Loss 8p	Loss	17	8	10	0.002²	0.455²	0.375²	0.945²
Loss 9p	WT	49	13	11	0.002²	0.069²	0.001²	0.220²
Loss 9p	Loss	15	10	17	0.002²	0.069²	0.001²	0.220²
Loss 9q	WT	51	13	11	0.001²	0.031²	< 0.001²	0.220²
Loss 9q	Loss	13	10	17	0.001²	0.031²	< 0.001²	0.220²
Loss 10q	WT	47	20	20	0.361²	0.186²	0.842²	0.180²
Loss 10q	Loss	17	3	8	0.361²	0.186²	0.842²	0.180²
Loss 14q	WT	48	13	15	0.076²	0.097²	0.042²	0.833²
Loss 14q	Loss	16	10	13	0.076²	0.097²	0.042²	0.833²
Tot. number of alterations	(median ± SD)	4 ± 2	4 ± 2	6 ± 3	0.157¹	0.934³	0.024³	0.050³

Differences between groups are compared using ¹Kruskall-Wallis Test, ²χ2-test and ³Mann-Whitney Test

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com